Efficacy and safety of BTK inhibitors in Richter’s transformation: a systematic review of clinical evidence
BTK inhibitor-based therapies show promising efficacy in patients with RT, particularly in combination with immunotherapeutic agents. While monotherapy may offer a tolerable option for frail patients, combination regimens may improve outcomes in select populations. Larger, randomized controlled trials are needed to better define the role of BTK inhibition in this high-risk disease.
Authors
- Venkatesh Gondhi
- F. Ajayi
- Canan Dirican (ORCID: https://orcid.org/0009-0008-6132-7759)
- Amara Sofia (ORCID: https://orcid.org/0009-0001-1075-7504)
- Ahmad Mardini
- Bolivia Crocete Aloysia Fernandes
- Hamid Shaaban
- Michael Maroules
Institutions
- University of Saint Mary (US)
- Saint Michael's Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3389/fonc.2025.1681589
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00